Pharmaron

OverviewSuggest Edit

Pharmaron (康龙化成) is a company operating as a contract research organization that supports the life science industry. It provides customers with pharmaceutical research and development services. The company specializes in synthetic, medicinal, and analytical chemistry, biology, pharmacology, drug safety assessment, and more.

TypePublic
Founded2004
HQBeijing, CN
Websitepharmaron.com
Employee Ratings3.6
Overall CultureA+

Latest Updates

Employees (est.) (Jun 2022)14,923(+36%)
Revenue (FY, 2021)¥7.4 B(+46%)
Share Price (Aug 2022)¥76.8(-1%)
Cybersecurity ratingCMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Pharmaron

Boliang Lou

Boliang Lou

Chairman, CEO
Larry Lou

Larry Lou

President & COO
Bei Zheng

Bei Zheng

Executive Vice President
Hua Yang

Hua Yang

Chief Scientific Officer
Gilbert Li

Gilbert Li

Chief Financial Officer
Connie Sun

Connie Sun

Senior Vice President Business & Corporate Development
Show more

Pharmaron Office Locations

Pharmaron has offices in Beijing, Ningbo, Shanghai, Tianjin and in 11 other locations
Beijing, CN (HQ)
6 Taihe Road
Beijing, CN
32 Kexue Yuan Road, Zhongguancun Life Science Park, Changping District
Ningbo, CN
Bldg 6, Tongji Industry Park, No. 7 of Binhai 2 Rd, Hangzhou Bay New Area
Shanghai, CN
3rd Fl, 2727 Jinke Rd, Pudong Xinqu
Tianjin, CN
81 Xin-Ye Seven Street, TEDA West Area
Xi'an, CN
No.1, 12th Fengcheng Road, Xi'an Export Processing Zone
Show all (16)

Pharmaron Financials and Metrics

Pharmaron Revenue

Embed Graph
View revenue for all periods
Pharmaron's revenue was reported to be ¥7.38 b in FY, 2021
CNY

Revenue (Q1, 2022)

2.1b

Gross profit (Q1, 2022)

681.8m

Gross profit margin (Q1, 2022), %

32.6%

Net income (Q1, 2022)

237.0m

EBITDA (Q1, 2022)

304.4m

EBIT (Q1, 2022)

354.0m

Market capitalization (2-Aug-2022)

57.6b

Closing stock price (2-Aug-2022)

76.8

Cash (31-Mar-2022)

2.9b

EV

60.0b
Pharmaron's current market capitalization is ¥57.6 b.
Annual
CNYFY, 2018FY, 2019FY, 2020FY, 2021

Revenue

2.9b3.7b5.1b7.4b

Cost of goods sold

(2.0b)(2.4b)(3.2b)(4.8b)

Gross profit

924.8m1.3b1.9b2.6b

Gross profit Margin, %

32%35%37%36%
Quarterly
CNYQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Revenue

754.4m855.8m992.2m950.1m1.2b1.4b1.5b1.8b2.0b2.1b

Cost of goods sold

(512.2m)(599.5m)(632.4m)(638.2m)(756.4m)(837.9m)(972.1m)(1.1b)(1.3b)(1.4b)

Gross profit

242.2m265.8m350.3m311.9m470.0m547.2m508.5m664.0m733.3m681.8m

Gross profit Margin, %

32%31%35%33%39%39%34%37%37%33%
Annual
CNYFY, 2018FY, 2019FY, 2020FY, 2021

Cash

320.7m4.5b2.9b3.5b

Accounts Receivable

655.4m857.1m1.1b1.2b

Prepaid Expenses

3.6m4.6m10.0m25.0m

Inventories

120.5m157.4m281.6m680.0m
Quarterly
CNYQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Cash

826.0m339.5m318.2m3.6b3.1b3.0b2.2b6.0b4.3b2.9b

Accounts Receivable

621.5m654.1m752.4m761.5m967.2m973.5m1.1b1.1b1.2b1.3b

Prepaid Expenses

6.4m9.5m5.6m5.5m12.7m10.3m15.0m17.3m29.7m24.6m

Inventories

153.2m257.3m263.3m189.1m231.3m257.3m318.8m445.3m567.6m788.6m
Annual
CNYFY, 2018FY, 2019FY, 2020FY, 2021

Net Income

332.8m530.7m1.1b1.6b

Depreciation and Amortization

210.1m262.9m304.8m404.6m

Inventories

(28.3m)(38.0m)(120.0m)(224.9m)

Accounts Payable

231.0m238.5m421.5m641.7m
Quarterly
CNYQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Net Income

156.7m466.6m547.3m

Depreciation and Amortization

125.6m145.9m184.2m

Inventories

(23.5m)(76.1m)(64.3m)

Accounts Payable

17.5m124.4m194.5m
CNYFY, 2018

Revenue/Employee

463.9k

Debt/Equity

0.7 x

Debt/Assets

0.3 x

Financial Leverage

2.1 x
Show all financial metrics

Pharmaron Operating Metrics

FY, 2019H1, 2020

Clients (R&D Service Platform)

1.04 k

New Clients (R&D Service Platform)

192190

Preclinical Projects (CMC Services)

485292

Projects (CMC Services)

568463

Pharmaron Acquisitions / Subsidiaries

Company NameDateDeal Size
LinkStartJuly 03, 2020
Shin Nippon Biomedical Laboratories Clinical Pharmacology Center, Inc.February 28, 2017
Xceleron IncJanuary 10, 2017
Quotient BioresearchFebruary 11, 2016
Bridge Laboratories ChinaJanuary 11, 2010
Beijing Xirui Biotechnology Co., Ltd
CR Medicon Research, Inc.
Nanjing Sirui Biotechnology Co., Ltd
Nanjing Ximaidi Medical Technology Co., Ltd.(
Phamaron (Tianjin) Process Development and Manufacturing Co., Ltd
Show more

Pharmaron Revenue Breakdown

Embed Graph

Pharmaron revenue breakdown by business segment: 61.5% from LABORATORY SERVICE, 23.5% from CMC, 12.9% from CLINICAL RESEARCH SERVICE and 2.0% from Other

Pharmaron revenue breakdown by geographic segment: 17.1% from CHINA (PEOPLES REPUBLIC) and 82.9% from REST OF WORLD

Pharmaron Cybersecurity Score

Cybersecurity ratingPremium dataset

C

73/100

SecurityScorecard logo

Pharmaron Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

CSRHub logo

Pharmaron Online and Social Media Presence

Embed Graph

Pharmaron Company Culture

  • Overall Culture

    A+

    89/100

  • CEO Rating

    A+

    100/100

  • Compensation

    A+

    100/100

Learn more on Comparably

Pharmaron News and Updates

“Wealth” Products Hurt Globally Acquisitive Pharmaron Beijing’s 1st Half Profit

Hong Kong-trade shares have lost nearly 36% in past year

Pharmaron Beijing Says Profit Rose Amid U.S., UK Expansion

Chinese-American billionaire Lou Boliang guides the way

OliX Pharmaceuticals Enters Agreement with Pharmaron to Advance Non-clinical Toxicology Testing for Hepatitis B Candidate OLX703A

Previous non-clinical pharmacology study demonstrated substantial reduction in serum markers of HBV Previous non-clinical pharmacology study demonstrated substantial reduction in serum markers of HBV

Pharmaron reopens RMB-linked CB market

Pharmaron Beijing Co brought the first renminbi-linked but dollar settled convertible bond to the market in nearly five years this week, raising $600m from the dual tranche deal.

Pharmaron Acquires State-of-the-Art Biomanufacturing Site in the United Kingdom from AbbVie

Pharmaron Beijing Co., Limited (Stock Code: 300759.SZ/3759.HK) (“Pharmaron”) announced today that it has entered into a definitive agreement to acquire Allergan Biologics Limited (“The ABL site”) in Liverpool, UK, for US$118.7 million in cash from AbbVie. The transaction is expected to close in the …

Pharmaron Acquires Majority Ownership in LinkStart

Pharmaron, a fully integrated contract research and manufacturing organization offering end-to-end R&D services for the life science industry, announced today that it completed a follow-on investment to acquire the majority ownership in Beijing LinkStart SMO Ltd.(Linkstart), a third party clinic…
Show more

Pharmaron Frequently Asked Questions

  • When was Pharmaron founded?

    Pharmaron was founded in 2004.

  • Who are Pharmaron key executives?

    Pharmaron's key executives are Boliang Lou, Larry Lou and Bei Zheng.

  • How many employees does Pharmaron have?

    Pharmaron has 14,923 employees.

  • What is Pharmaron revenue?

    Latest Pharmaron annual revenue is ¥7.4 b.

  • What is Pharmaron revenue per employee?

    Latest Pharmaron revenue per employee is ¥494.2 k.

  • Who are Pharmaron competitors?

    Competitors of Pharmaron include BBCA Group, WuXi AppTec and Akums.

  • Where is Pharmaron headquarters?

    Pharmaron headquarters is located at 6 Taihe Road, Beijing.

  • Where are Pharmaron offices?

    Pharmaron has offices in Beijing, Ningbo, Shanghai, Tianjin and in 11 other locations.

  • How many offices does Pharmaron have?

    Pharmaron has 16 offices.